Back

Pomerantz investigates Emergent BioSolutions after stock plunges 29.58%

Verifying
  • Pomerantz LLP is investigating Emergent BioSolutions and certain officers and directors over possible securities violations.
  • $191.3 million non-cash impairment contributed to Emergent's $180.2 million GAAP net loss.
  • Emergent cut full-year revenue guidance by approximately 10.8% at the midpoint on Aug. 5, 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.